Valneva (NASDAQ:VALN) Cut to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Valneva (NASDAQ:VALN) from a strong-buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France. “

Several other research firms also recently commented on VALN. UBS Group downgraded shares of Valneva from a neutral rating to a sell rating in a research note on Wednesday, December 22nd. Jefferies Financial Group began coverage on shares of Valneva in a research note on Friday, September 24th. They issued a buy rating and a $39.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Valneva presently has a consensus rating of Hold and an average target price of $41.25.

Shares of NASDAQ VALN opened at $37.44 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.23 and a quick ratio of 0.95. Valneva has a 52-week low of $24.16 and a 52-week high of $67.84. The business’s 50 day moving average is $50.75 and its two-hundred day moving average is $39.47.

Hedge funds have recently modified their holdings of the stock. Laurion Capital Management LP acquired a new position in shares of Valneva during the second quarter worth $659,000. CVI Holdings LLC acquired a new position in shares of Valneva during the second quarter worth $1,486,000. Millennium Management LLC acquired a new position in shares of Valneva during the second quarter worth $259,000. Morgan Stanley acquired a new position in shares of Valneva during the third quarter worth $97,000. Finally, Granite Point Capital Management L.P. acquired a new position in shares of Valneva during the third quarter worth $376,000. Hedge funds and other institutional investors own 0.50% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium.

Featured Article: What is an overbought condition?

Get a free copy of the Zacks research report on Valneva (VALN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Valneva (NASDAQ:VALN)

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.